The first FDA accelerated approval of an ICI for breast cancer was with the anti-PD-L1 inhibitor atezolizumab, which was granted on 8 March 2019[32] based on the IMpassion 130 trial[33]. This evidence concerns the gene CD274 and breast cancer.